Advanced search
Publication Cover
Biomarkers in Medicine Volume 1, 2007 - Issue 3
Submit an article Journal homepage
265
Views
0
CrossRef citations to date
0
Altmetric
Review

Assessing the Clinical Utility of Biomarkers in Medicine

Nisha I Parikh1 Framingham Heart Study,73 Mount Wayte Avenue, Suite 2,Framingham,MA 01702-5803,USA.View further author information
&
Ramachandran S Vasan1 Framingham Heart Study,73 Mount Wayte Avenue, Suite 2,Framingham,MA 01702-5803,USA.;2 Boston University School of Medicine, Preventive Medicine Section,Boston, MA,USACorrespondence[email protected]
View further author information
Pages 419-436 | Published online: 05 Nov 2007

Bibliography

  • Biomarkers D efinitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69(3), 89–95 (2001).
  • Vasan RS : Biomarkers of cardiovascular disease: molecular basis and practical considerations.Circulation113(19), 2335–2362 (2006).
  • Miremadi S , SnidermanA, FrohlichJ: Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?Clin. Chem.48(3), 484–488 (2002).
  • Hu FB , WillettWC: Optimal diets for prevention of coronary heart disease.JAMA288(20), 2569–2578 (2002).
  • Baigent C , KeechA, KearneyPM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366(9493), 1267–1278 (2005).
  • Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA285(19), 2486–2497 (2001).
  • Manolio T : Novel risk markers and clinical practice.N. Engl. J. Med.349(17), 1587–1589 (2003).
  • Loong TW : Understanding sensitivity and specificity with the right side of the brain.BMJ327(7417), 716–719 (2003).
  • Sackett DL , HaynesRB, GuyattGH, TugwellP: The interpretation of diagnostic data. In: Clinical Epidemiology, a Basic Science for Clinical Medicine (2nd Edition). Little Brown, Boston, USA 69–152 (1991).
  • Lindahl B , VengeP, WallentinL: Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group.Circulation93(9), 1651–1657 (1996).
  • Galvani M , OttaniF, FerriniD et al.: Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation95(8), 2053–2059 (1997).
  • Newby LK , ChristensonRH, OhmanEM et al.: Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation98(18), 1853–1859 (1998).
  • De Backer G , AmbrosioniE, Borch-JohnsenKet al.: European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice. Eur. Heart. J.24(17), 1601–1610 (2003).
  • Wilson PW , D‘AgostinoRB, LevyD, BelangerAM, SilbershatzH, KannelWB: Prediction of coronary heart disease using risk factor categories.Circulation97(18), 1837–1847 (1998).
  • Greenland P , BonowRO, BrundageBHet al.: ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J. Am. Coll. Cardiol.49(3), 378–402 (2007).
  • Antman EM , CohenM, BerninkPJet al.: The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA284(7), 835–842 (2000).
  • Lee DS , AustinPC, RouleauJL, LiuPP, NaimarkD, TuJV: Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.JAMA290(19), 2581–2587 (2003).
  • Levy WC , MozaffarianD, LinkerDTet al.: The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation113(11), 1424–1433 (2006).
  • Fonarow GC , AdamsKFJr, AbrahamWT, YancyCW, BoscardinWJ: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA293(5), 572–580 (2005).
  • Pencina MJ , D‘AgostinoRB: Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.Stat. Med.23(13), 2109–2123 (2004).
  • Hanley JA , McNeilBJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve.Radiology143(1), 29–36 (1982).
  • Baker SG : The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer.J. Natl Cancer Inst.95(7), 511–515 (2003).
  • Folsom AR , ChamblessLE, BallantyneCMet al.: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch. Intern. Med.166(13), 1368–1373 (2006).
  • Lloyd-Jones DM , LiuK, TianL, GreenlandP: Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann. Intern. Med.145(1), 35–42 (2006).
  • Danesh J , WheelerJG, HirschfieldGMet al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med.350(14), 1387–1397 (2004).
  • Koenig W , LowelH, BaumertJ, MeisingerC: C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation109(11), 1349–1353 (2004).
  • Pepe MS , JanesH, LongtonG, LeisenringW, NewcombP: Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am. J. Epidemiol.159(9), 882–890 (2004).
  • Ridker PM , RifaiN, RoseL, BuringJE, CookNR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.N. Engl. J. Med.347(20), 1557–1565 (2002).
  • Rutter MK , MeigsJB, SullivanLM, D‘AgostinoRBSr, WilsonPW: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation110(4), 380–385 (2004).
  • Shlipak MG , FriedLF, CushmanMet al.: Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA293(14), 1737–1745 (2005).
  • van der Meer IM , De MaatMP, KiliaanAJ, van der KuipDA, HofmanA, WittemanJC: The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch. Intern. Med.163(11), 1323–1328 (2003).
  • Wilson PW , NamBH, PencinaM, D‘AgostinoRBSr, BenjaminEJ, O‘DonnellCJ: C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch. Intern. Med.165(21), 2473–2478 (2005).
  • Cook NR : Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation115(7), 928–935 (2007).
  • Wald NJ , HackshawAK, FrostCD: When can a risk factor be used as a worthwhile screening test?BMJ319(7224), 1562–1565 (1999).
  • Cook NR , BuringJE, RidkerPM: The effect of including C-reactive protein in cardiovascular risk prediction models for women.Ann. Intern. Med.145(1), 21–29 (2006).
  • Justice AC , CovinskyKE, BerlinJA: Assessing the generalizability of prognostic information.Ann. Intern. Med.130(6), 515–24 (1999).
  • Hosmer DW , HosmerT, Le CessieS, LemeshowS: A comparison of goodness-of-fit tests for the logistic regression model. Stat. Med.16(9), 965–980 (1997).
  • Pencina M , D‘AgastinoRBSr, D‘AgastinoRBJr, VasanRS: Evaluating the added predictive ability of a new marker: from the area under the ROC curve to reclassification and beyond. Stat. Med. DOI:10.1002/sim.2929 (2007) (Epub ahead of print).
  • D‘Agostino RB Sr , GrundyS, SullivanLM, WilsonP: Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA286(2), 180–187 (2001).
  • Guder G , BauersachsJ, FrantzSet al.: Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation115(13), 1754–1761 (2007).
  • Kistorp C , RaymondI, PedersenF, GustafssonF, FaberJ, HildebrandtP: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.JAMA293(13), 1609–1616 (2005).
  • Wang TJ , GonaP, LarsonMGet al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med.355(25), 2631–2639 (2006).
  • Newby LK , StorrowAB, GiblerWBet al.: Bedside multimarker testing for risk stratification in chest pain units: the chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation103(14), 1832–1837 (2001).
  • Kip KE , MarroquinOC, ShawLJet al.: Global inflammation predicts cardiovascular risk in women: a report from the Womens Ischemia Syndrome Evaluation (WISE) study. Am. Heart J.150(5), 900–906 (2005).
  • Bodi V , SanchisJ, LlacerAet al.: Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST-elevation acute coronary syndromes. Am. Heart J.149(2), 268–274 (2005).
  • Voss R , CullenP, SchulteH, AssmannG: Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks.Int. J. Epidemiol.31(6), 1253–1262 (2002).
  • Cook SA , RosenzweigA: DNA microarrays: implications for cardiovascular medicine.Circ. Res.91(7), 559–564 (2002).
  • Hanash S : HUPO initiatives relevant to clinical proteomics.Mol. Cell Proteomics3(4), 298–301 (2004).
  • Service RF : Pharmacogenomics. Going from genome to pill.Science308(5730), 1858–1860 (2005).
  • Weinshilboum R : Inheritance and drug response.N. Engl. J. Med.348(6), 529–537 (2003).
  • Rieder MJ , ReinerAP, GageBFet al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med.352(22), 2285–2293 (2005).
  • Noble D : Modeling the heart – from genes to cells to the whole organ.Science295(5560), 1678–1682 (2002).
  • Quackenbush J : Computational analysis of microarray data.Nat. Rev. Genet.2(6), 418–427 (2001).
  • Lamarche B , MoorjaniS, LupienPJet al.: Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the quebec cardiovascular study. Circulation94(3), 273–278 (1996).
  • Pischon T , GirmanCJ, SacksFM, RifaiN, StampferMJ, RimmEB: Non-high-density lipoprotein cholesterol and apolipoprotein b in the prediction of coronary heart disease in men.Circulation112(22), 3375–3383 (2005).
  • Shai I , RimmEB, HankinsonSEet al.: Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation110(18), 2824–2830 (2004).
  • Sharrett AR , BallantyneCM, CoadySAet al.: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation104(10), 1108–1113 (2001).
  • Talmud PJ , HaweE, MillerGJ, HumphriesSE: Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler. Thromb. Vasc. Biol.22(11), 1918–1923 (2002).
  • Walldius G , JungnerI, HolmeI, AastveitAH, KolarW, SteinerE: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet358(9298), 2026–2033 (2001).
  • Ballantyne CM , AndrewsTC, HsiaJA, KramerJH, ShearC: Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels.Am. J. Cardiol.88(3), 265–269 (2001).
  • Gotto AM Jr , WhitneyE, SteinEAet al.: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation101(5), 477–484 (2000).
  • Simes RJ , MarschnerIC, HuntDet al.: Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (lipid) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation105(10), 1162–1169 (2002).
  • Danesh J , CollinsR, PetoR: Lipoprotein(a) and coronary heart disease : meta-analysis of prospective studies.Circulation102(10), 1082–1085 (2000).
  • Blake GJ , OtvosJD, RifaiN, RidkerPM: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women.Circulation106(15), 1930–1937 (2002).
  • Kuller L , ArnoldA, TracyRet al.: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol.22(7), 1175–1180 (2002).
  • Gaziano JM , HennekensCH, O‘DonnellCJ, BreslowJL, BuringJE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation96(8), 2520–2525 (1997).
  • Jeppesen J , HeinHO, SuadicaniP, GyntelbergF: Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease.Arch. Intern. Med.161(3), 361–366 (2001).
  • Jeppesen J , HeinHO, SuadicaniP, GyntelbergF: Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study.Arterioscler. Thromb. Vasc. Biol.17(6), 1114–1120 (1997).
  • Jeppesen J , HeinHO, SuadicaniP, GyntelbergF: High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease.Am. Heart J.145(1), 103–108 (2003).
  • Tan MH , JohnsD, GlazerNB: Pioglitazone reduces atherogenic index of plasma in patients with Type 2 diabetes.Clin. Chem.50(7), 1184–1188 (2004).
  • Shand B , ScottR, ConnollySet al.: Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes. Diabetes Obes. Metab.9(4), 540–547 (2007).
  • Boekholdt SM , KuivenhovenJA, WarehamNJet al.: Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women. The prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk Population study. Circulation110(11), 1418–1423 (2004).
  • Ballantyne CM , HoogeveenRC, BangHet al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation109(7), 837–842 (2004).
  • Ballantyne CM , HoogeveenRC, BangHet al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Arch. Intern. Med.165(21), 2479–2484 (2005).
  • Blake GJ , DadaN, FoxJC, MansonJE, RidkerPM: A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women.J. Am. Coll. Cardiol.38(5), 1302–1306 (2001).
  • Boekholdt SM , KellerTT, WarehamNJet al.: Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler. Thromb. Vasc. Biol.25(4), 839–846 (2005).
  • Brilakis ES , McConnellJP, LennonRJ, ElesberAA, MeyerJG, BergerPB: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up.Eur. Heart J.26(2), 137–144 (2005).
  • Koenig W , KhuseyinovaN, LowelH, TrischlerG, MeisingerC: Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.Circulation110(14), 1903–1908 (2004).
  • Oei HH , van der MeerIM, HofmanAet al.: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation111(5), 570–575 (2005).
  • Schaefer EJ , McNamaraJR, AsztalosBFet al.: Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am. J. Cardiol.95(9), 1025–1032 (2005).
  • Tsimihodimos V , KarabinaSA, TambakiAPet al.: Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler. Thromb. Vasc. Biol.22(2), 306–311 (2002).
  • Danesh J , WheelerJG, HirschfieldGMet al.: C-Reactive Protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med.350(14), 1387–1397 (2004).
  • Smith SC Jr , BlairSN, BonowROet al.: AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation104(13), 1577–1579 (2001).
  • Malik I , DaneshJ, WhincupPet al.: Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet358(9286), 971–976 (2001).
  • Cesari M , PenninxBWJH, NewmanABet al.: Inflammatory markers and onset of cardiovascular events: results from the health ABC Study. Circulation108(19), 2317–2322 (2003).
  • Pai JK , PischonT, MansonJEet al.: Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med.351(25), 2599–2610 (2004).
  • Pradhan AD , MansonJE, RossouwJEet al.: Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Womens‘ Health Initiative observational study. JAMA288(8), 980–987 (2002).
  • Ridker PM , RifaiN, StampferMJ, HennekensCH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.Circulation101(15), 1767–1772 (2000).
  • Volpato S , GuralnikJM, FerrucciLet al.: Cardiovascular disease, interleukin-6, and risk of mortality in older women: the womens‘ health and aging study. Circulation103(7), 947–953 (2001).
  • Blankenberg S , TiretL, BickelCet al.: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation106(1), 24–30 (2002).
  • Blankenberg S , LucG, DucimetierePet al.: Interleukin-18 and the risk of coronary heart disease in European men: the prospective epidemiological study of myocardial infarction (PRIME). Circulation108(20), 2453–2459 (2003).
  • Biasucci LM , LiuzzoG, GrilloRLet al.: Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation99(7), 855–860 (1999).
  • Haverkate E , ThompsonSG, PykeSD, GallimoreJR, GroupMBP: Production of C-reactive protein and risk of coronary events in stable and unstable angina.Lancet349(9050), 462–466 (1997).
  • Johnson BD , KipKE, MarroquinOCet al.: Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-sponsored Womens‘ Ischemia Syndrome Evaluation (WISE). Circulation109(6), 726–732 (2004).
  • Baldus S , HeeschenC, MeinertzTet al.: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation108(12), 1440–1445 (2003).
  • Brennan ML , PennMS, Van LenteFet al.: Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med.349(17), 1595–1604 (2003).
  • Zhang R , BrennanML, FuXet al.: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA286(17), 2136–2142 (2001).
  • Heeschen C , DimmelerS, HammCWet al.: Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med.348(12), 1104–1111 (2003).
  • Schonbeck U , VaroN, LibbyP, BuringJ, RidkerPM: Soluble CD40L and cardiovascular risk in women.Circulation104(19), 2266–2268 (2001).
  • Varo N , LibbyP, MorrowDAet al.: Soluble CD40L: risk prediction after acute coronary syndromes. Circulation108(9), 1049–1052 (2003).
  • Yan JC , ZhuJ, GaoLet al.: The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes. Clin. Chim. Acta343(1–2) , 155–159 (2004).
  • Kinlay S , SchwartzGG, OlssonAGet al.: Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study. Circulation110(4), 386–391 (2004).
  • Sanguigni V , PignatelliP, LentiLet al.: Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation111(4), 412–419 (2005).
  • Meisinger C , BaumertJ, KhuseyinovaN, LoewelH, KoenigW: Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population.Circulation112(5), 651–657 (2005).
  • Blankenberg S , RupprechtHJ, BickelCet al.: Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N. Engl. J. Med.349(17), 1605–1613 (2003).
  • Schnabel R , LacknerKJ, RupprechtHJet al.: Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: results from the Atherogene study. J. Am. Coll. Cardiol.45(10), 1631–1637 (2005).
  • Shishehbor MH , AvilesRJ, BrennanMLet al.: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA289(13), 1675–1680 (2003).
  • Homocysteine S tudies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA288(16), 2015–2022 (2002).
  • Wald DS , LawM, MorrisJK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.BMJ325(7374), 1202–1206 (2002).
  • Koenig W , TwardellaD, BrennerH, RothenbacherD: Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.Clin. Chem.51(2), 321–327 (2005).
  • Luc G , BardJM, LesueurCet al.: Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis (In Press) (2007).
  • O‘Hare AM , NewmanAB, KatzRet al.: Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch. Intern. Med.165(22), 2666–2670 (2005).
  • Shlipak MG , SarnakMJ, KatzRet al.: Cystatin C and the risk of death and cardiovascular events among elderly persons. N. Engl. J. Med.352(20), 2049–2060 (2005).
  • Omland T , RichardsAM, WergelandR, Vik-MoH: B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease.Am. J. Cardiol.95(1), 24–28 (2005).
  • Suzuki S , YoshimuraM, NakayamaMet al.: Plasma level of b-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation110(11), 1387–1391 (2004).
  • Galvani M , OttaniF, OltronaLet al.: N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation110(2), 128–134 (2004).
  • Heeschen C , HammCW, MitrovicV, LantelmeNH, WhiteHD, Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators: N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation110(20), 3206–3212 (2004).
  • Kistorp C , RaymondI, PedersenF, GustafssonF, FaberJ, HildebrandtP: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.JAMA293(13), 1609–1616 (2005).
  • Kragelund C , GronningB, HildebrandtP, KoberL, SteffensenR: N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.N. Engl. J. Med.352(7), 666–675 (2005).
  • Morrow DA , SabatineMS, McCabeCHet al.: Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J. Am. Coll. Cardiol.41(8), 1264–1272 (2003).
  • Morrow DA , de LemosJA, BlazingMAet al.: Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA294(22), 2866–2871 (2005).
  • Sabatine MS , MorrowDA, de LemosJAet al.: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation105(15), 1760–1763 (2002).
  • Wang TJ , LarsonMG, LevyDet al.: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med.350(7), 655–663 (2004).
  • de Lemos JA , MorrowDA, BentleyJHet al.: The prognostic value of b-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med.345(14), 1014–1021 (2001).
  • Gackowski A , IsnardR, GolmardJLet al.: Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur. Heart J.25(20), 1788–1796 (2004).
  • Logeart D , ThabutG, JourdainPet al.: Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol.43(4), 635–641 (2004).
  • Troughton RW , FramptonCM, YandleTG, EspineEA, NichollsMG, RichardsAM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.Lancet355(9210), 1126–1130 (2000).
  • Bae SW , StuhlingerMC, YooHSet al.: Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during 2 weeks of medical treatment. Am. J. Cardiol.95(6), 729–733 (2005).
  • Boger RH , ZoccaliC: ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.Atheroscler. Suppl.4(4), 23–28 (2003).
  • Krempl TK , MaasR, SydowK, MeinertzT, BogerRH, KahlerJ: Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events.Eur. Heart. J.26(18), 1846–1851 (2005).
  • Mallamaci F , TripepiG, CutrupiS, MalatinoLS, ZoccaliC: Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD.Kidney Int.67(6), 2330–2337 (2005).
  • Ravani P , TripepiG, MalbertiF, TestaS, MallamaciF, ZoccaliC: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.J. Am. Soc. Nephrol.16(8), 2449–2455 (2005).
  • Tarnow L , HovindP, TeerlinkT, StehouwerCD, ParvingHH: Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care27(3), 765–769 (2004).
  • Valkonen VP , PaivaH, SalonenJTet al.: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet358(9299), 2127–2128 (2001).
  • Zoccali C , Bode-BogerS, MallamaciFet al.: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet358(9299), 2113–2117 (2001).
  • Atwood LD , Heard-CostaNL: Limits of fine-mapping a quantitative trait.Genet. Epidemiol.24(2), 99–106 (2003).
  • Blankenberg S , RupprechtHJ, PoirierOet al.: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation107(12), 1579–1585 (2003).
  • Lubos E , SchnabelR, RupprechtHJet al.: Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur. Heart J.27(2), 150–156 (2006).
  • O‘Leary DH , PolakJF, KronmalRAet al.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N. Engl. J. Med.340(1), 14–22 (1999).
  • Bots ML , HoesAW, KoudstaalPJ, HofmanA, GrobbeeDE: Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation96(5), 1432–1437 (1997).
  • Chambless LE , HeissG, FolsomARet al.: Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am. J. Epidemiol.146(6), 483–494 (1997).
  • Hodis HN , MackWJ, LaBreeLet al.: The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med.128(4), 262–269 (1998).
  • Lonn E : Use of carotid ultrasound to stratify risk.Can. J. Cardiol. (Suppl. A) , 22A–25A (2001).
  • Mancini GB : Carotid intima-media thickness as a measure of vascular target organ damage.Curr. Hypertens. Rep.2(1), 71–77 (2000).
  • Mukherjee D , YadavJS: Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification.Am. Heart J.144(5), 753–759 (2002).
  • Arad Y , SpadaroLA, GoodmanKet al.: Predictive value of electron beam computed tomography of the coronary arteries: 19-month follow-up of 1173 asymptomatic subjects. Circulation93(11), 1951–1953 (1996).
  • Arad Y , GoodmanKJ, RothM, NewsteinD, GuerciAD: Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: The St. Francis Heart Study. J. Am. Coll. Cardiol.46(1), 158–165 (2005).
  • Greenland P , LaBreeL, AzenSP, DohertyTM, DetranoRC: Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA291(2), 210–215 (2004).
  • Kondos GT , HoffJA, SevrukovAet al.: Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation107(20), 2571–2576 (2003).
  • Vliegenthart R , OudkerkM, HofmanAet al.: Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation112(4), 572–577 (2005).
  • Prospective S tudies C: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360(9349), 1903–1913 (2002).
  • Bonetti PO , LermanLO, LermanA: Endothelial dysfunction: a marker of atherosclerotic risk.Arterioscler. Thromb. Vasc. Biol.23(2), 168–175 (2003).
  • Brevetti G , SilvestroA, SchianoV, ChiarielloM: Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index.Circulation108(17), 2093–2098 (2003).
  • Chan SY , ManciniGB, KuramotoL, SchulzerM, FrohlichJ, IgnaszewskiA: The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease.J. Am. Coll. Cardiol.42(6), 1037–1043 (2003).
  • Fichtlscherer S , BreuerS, ZeiherAM: Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the ’vulnerable‘ patient.Circulation110(14), 1926–1932 (2004).
  • Gokce N , KeaneyJFJr, HunterLM, WatkinsMT, MenzoianJO, VitaJA: Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation105(13), 1567–1772 (2002).
  • Gokce N , KeaneyJFJr, HunterLMet al.: Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J. Am. Coll. Cardiol.41(10), 1769–1775 (2003).
  • Halcox JP , SchenkeWH, ZalosGet al.: Prognostic value of coronary vascular endothelial dysfunction. Circulation106(6), 653–658 (2002).
  • Heitzer T , SchlinzigT, KrohnK, MeinertzT, MunzelT: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation104(22), 2673–2678 (2001).
  • Neunteufl T , HeherS, KatzenschlagerRet al.: Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am. J. Cardiol.86(2), 207–210 (2000).
  • Perticone F , CeravoloR, PujiaAet al.: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation104(2), 191–196 (2001).
  • Schachinger V , BrittenMB, ZeiherAM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.Circulation101(16), 1899–1906 (2000).
  • Schindler TH , HornigB, BuserPTet al.: Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiograms. Arterioscler. Thromb. Vasc. Biol.23(3), 495–501 (2003).
  • Suwaidi JA , HamasakiS, HiganoST, NishimuraRA, HolmesDRJr, LermanA: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation101(9), 948–954 (2000).
  • Targonski PV , BonettiPO, PumperGM, HiganoST, HolmesDRJr, LermanA: Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation107(22), 2805–2809 (2003).
  • Verma S , BuchananMR, AndersonTJ: Endothelial function testing as a biomarker of vascular disease.Circulation108(17), 2054–2059 (2003).
  • von Mering GO , ArantCB, WesselTRet al.: Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-sponsored Womens‘ Ischemia Syndrome Evaluation (WISE). Circulation109(6), 722–725 (2004).
  • Modena MG , BonettiL, CoppiF, BursiF, RossiR: Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women.J. Am. Coll. Cardiol.40(3), 505–510 (2002).
  • Blacher J , AsmarR, DjaneS, LondonGM, SafarME: Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients.Hypertension33(5), 1111–1117 (1999).
  • Boutouyrie P , TropeanoAI, AsmarRet al.: Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension39(1), 10–15 (2002).
  • Grey E , BratteliC, GlasserSPet al.: Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am. J. Hypertens.16(4), 265–259 (2003).
  • London GM , BlacherJ, PannierB, GuerinAP, MarchaisSJ, SafarME: Arterial wave reflections and survival in end-stage renal failure. Hypertension38(3), 434–438 (2001).
  • Safar ME , BlacherJ, PannierBet al.: Central pulse pressure and mortality in end-stage renal disease. Hypertension39(3), 735–738 (2002).
  • Stork S , van den BeldAW, von SchackyCet al.: Carotid artery plaque burden, stiffness, and mortality risk in elderly men: a prospective, population-based cohort study. Circulation110(3), 344–348 (2004).
  • Weber T , AuerJ, O‘RourkeMFet al.: Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation109(2), 184–189 (2004).
  • Weber T , AuerJ, O‘RourkeMFet al.: Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions. Eur. Heart J.26(24), 2657–2663 (2005).
  • Schiffrin EL , ParkJB, IntenganHD, TouyzRM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation101(14), 1653–1659 (2000).
  • Doobay AV , AnandSS: Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review.Arterioscler. Thromb. Vasc. Biol.25(7), 1463–1469 (2005).
  • Criqui MH , LangerRD, FronekAet al.: Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med.326(6), 381–386 (1992).
  • Agodoa LY , AppelL, BakrisGLet al.: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA285(21), 2719–2728 (2001).
  • Arnlov J , EvansJC, MeigsJBet al.: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation112(7), 969–975 (2005).
  • Ballard DJ , HumphreyLL, MeltonLJet al.: Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes37(4), 405–412 (1988).
  • Borch-Johnsen K , Feldt-RasmussenB, StrandgaardS, SchrollM, JensenJS: Urinary albumin excretion : an independent predictor of ischemic heart disease.Arterioscler. Thromb. Vasc. Biol.19(8), 1992–1997 (1999).
  • Miettinen H , HaffnerSM, LehtoS, RonnemaaT, PyoralaK, LaaksoM: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and noninsulin-dependent diabetic subjects.Stroke27(11), 2033–2039 (1996).
  • Mogensen CE : Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.N. Engl. J. Med.310(6), 356–360 (1984).
  • Neil A , HawkinsM, PotokM, ThorogoodM, CohenD, MannJ: A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care16(7), 996–1003 (1993).
  • Nelson RG , PettittDJ, CarraherMJ, BairdHR, KnowlerWC: Effect of proteinuria on mortality in NIDDM. Diabetes37(11), 1499–1504 (1988).
  • Fibrinogen SC : Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.JAMA294(14), 1799–1809 (2005).
  • Danesh J , WhincupP, WalkerMet al.: Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation103(19), 2323–2327 (2001).
  • Lowe GDO , DaneshJ, LewingtonSet al.: Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur. Heart J.25(3), 252–259 (2004).
  • Whincup PH , DaneshJ, WalkerMet al.: von Willebrand factor and coronary heart disease. Prospective study and meta-analysis. Eur. Heart J.23(22), 1764–1670 (2002).
  • Aronow BJ , ToyokawaT, CanningAet al.: Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy. Physiol. Genomics6(1), 19–28 (2001).
  • Bikkina M , LevyD, EvansJCet al.: Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA272(1), 33–36 (1994).
  • Kannel WB , AbbottRD: A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study.Am. Heart J.111(2), 391–397 (1986).
  • Koren MJ , DevereuxRB, CasalePN, SavageDD, LaraghJH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med.114(5), 345–352 (1991).
  • Levy D , GarrisonRJ, SavageDD, KannelWB, CastelliWP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med.322(22), 1561–1566 (1990).
  • Liao Y , CooperRS, McGeeDL, MensahGA, GhaliJK: The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA273(20), 1592–1597 (1995).
  • Quinones MA , GreenbergBH, KopelenHAet al.: Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of left ventricular dysfunction. J. Am. Coll. Cardiol.35(5), 1237–1244 (2000).
  • Schillaci G , VerdecchiaP, PorcellatiC, CuccurulloO, CoscoC, PerticoneF: Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension.Hypertension35(2), 580–586 (2000).
  • Vakili BA , OkinPM, DevereuxRB: Prognostic implications of left ventricular hypertrophy.Am. Heart J.141(3), 334–341 (2001).
  • Mathew J , SleightP, LonnEet al.: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation104(14), 1615–1621 (2001).
  • Okin PM , DevereuxRB, JernSet al.: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA292(19), 2343–2349 (2004).
  • Verdecchia P , SchillaciG, BorgioniCet al.: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation97(1), 48–54 (1998).
  • Ekelund LG , SuchindranCM, McMahonRPet al.: Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. J. Am. Coll. Cardiol.14(3), 556–563 (1989).
  • Gibbons LW , MitchellTL, WeiM, BlairSN, CooperKH: Maximal exercise test as a predictor of risk for mortality from coronary heart disease in asymptomatic men. Am. J. Cardiol.86(1), 53–58 (2000).
  • Rautaharju PM , PrineasRJ, EiflerWJet al.: Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. J. Am. Coll. Cardiol.8(1), 1–10 (1986).
  • Heidenreich PA , AlloggiamentoT, MelsopK, McDonaldKM, GoAS, HlatkyMA: The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J. Am. Coll. Cardiol.38(2), 478–185 (2001).
  • Scirica BM , MorrowDA: Troponins in acute coronary syndromes.Prog. Cardiovasc. Dis.47(3), 177–188 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.